用恩塔卡抑制catechol-O-methyltransferase:来自帕金森病受控临床试验的证据
1Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.
European journal of neurology
|July 26, 2023
概括
恩塔卡是一种甲基转移酶 (catechol-O-methyltransferase) 抑制剂,通过增加ON时间和减少OFF时间,有效地控制帕金森病的运动波动. 它改善了勒沃多巴治疗患者的运动功能和生活质量.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 在接受levodopa治疗的患者中经常涉及运动波动.
- 磨损现象显著影响日常生活和生活质量.
研究的目的:
- 评估恩塔卡作为帕金森病运动波动的辅助治疗的疗效.
- 评估恩塔卡对运动控制,日常生活活动和生活质量的影响.
主要方法:
- 分析了五项随机的安慰剂受控试验,涉及1000多名患者.
- 审查额外的试验检查entacapone在运动波动的不同阶段.
主要成果:
- 附加的恩塔卡显著增加了ON时间 (0.71.6小时) 并减少了OFF时间.
- 观察到ON运动功能,日常生活活动和生活质量的改善.
- 早期使用恩塔卡并没有延迟动力障碍的发作;可能发生多巴诱导的不良事件,可通过剂量调整进行管理.
结论:
- 恩塔卡是一种一线辅助疗法,用于管理帕金森病的磨损运动波动.
- 使用乐伏多巴,卡比多巴和恩塔卡 (LCE) 的联合治疗提供了一个综合治疗选择.
- 恩塔卡增强了多巴胺活性,改善了PD患者的治疗结果.
相关概念视频
Parkinson's Disease: Treatment
301
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
301
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Parkinson's Disease: Overview
599
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
599
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.9K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.9K
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Enzyme Inhibition
78.7K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.7K


